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A DCE-MRI Driven 3-D Reaction-Diffusion Model
of Solid Tumour Growth
Thaı´s Roque1, Laurent Risser2, Veerle Kersemans3, Sean Smart3, Danny Allen3, Paul Kinchesh3,
Stuart Gilchrist3, Ana L. Gomes3, Julia A. Schnabel1,4, Member, IEEE, Michael A. Chappell1
Abstract—Predicting tumour growth and its response to therapy
remains a major challenge in cancer research and strongly relies
on tumour growth models. In this work, we introduce, calibrate
and verify a novel image-driven reaction-diffusion model of
avascular tumour growth. The model allows for proliferation,
death and spread of tumour cells, and accounts for nutrient
distribution and hypoxia. It is constrained by longitudinal time
series of DCE-MRI images. Tumour specific parameters are
estimated from two early time points and used to predict the
spatio-temporal evolution of the tumour volume and cell densities
at later time points. We first test our parameter estimation
approach on synthetic data from 15 generated tumours. Our
in silico study resulted in small volume errors (< 5%) and high
Dice overlaps (>97%), showing that model parameters can be
successfully recovered and used to accurately predict tumour
growth. Encouraged by these results, we apply our model to
seven pre-clinical cases of breast carcinoma. We are able to
show promising preliminary results, especially for the estimation
for early time points. Processes like angiogenesis and apoptosis
should be included to further improve predictions for later time
points.
Index Terms—Animal models and imaging, Magnetic resonance
imaging (MRI), Quantification and estimation, Tissue modelling
I. INTRODUCTION
CANCER is a leading cause of death worldwide. It can beseen as a progressive multistep transformation process
that incorporates biological changes happening at different
spatial and temporal scales. Mathematical models of tumour
growth provide a framework within which this biological sys-
tem can be analysed. Broadly speaking, mathematical models
can be classified into two categories depending on the scale the
focus resides on: microscopic and macroscopic models.
The first category describes the evolution of each tumour
cell by different biological functions and activities to elucidate
the microscopic aspect of tumour growth. Models can range
from simple exponential, logistic and Gompertzian growth
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laws to elaborate systems of partial differential equations
describing the growth of a tumour and its invasion into the
surrounding tissue [5], [8], [18], [22].
Although these models can provide helpful insights into
tumour biology, their clinical usefulness is fundamentally
limited. This is because the majority of these models rely on
knowledge of processes occurring at the sub-cellular or cellular
scales, such as chemotaxis, haptotaxis or growth factors, which
are difficult or even impossible to measure in an intact living
system and cannot be observed in medical images.
The second category includes continuum models that de-
scribe tumour growth at the macroscopic level. The majority of
the current macroscopic models of tumour growth have been
applied to the case of glioma growth [7], [11]–[13], [15], [24],
[25], [28]. Formulated based on Murray’s reaction-diffusion
formalism [17], they describe the temporal evolution of tumour
cell densities at different locations through diffusion, migration
and proliferation of cells.
By describing the evolution of cell groups rather than
of each individual cell, these models provide a framework
which allows for integration of medical imaging data. In order
to personalise such a model, the estimation of parameters
using longitudinal data can be performed to predict subsequent
evolution. Here, evolution can be defined as cellular, volumet-
ric, or tumour delineation progression. Most groups initialise
their models with cellular densities but use a macroscopic,
observable quantity of interest (e.g. radial or middle slice
evolution) for validation [7], [11], [13], [24], [28]. Following
the idea that in the images only the evolution of tumour
boundaries but not the tumour cell densities can be observed,
other studies have chosen to parametrise their models by
following the motion of the tumour delineation [15].
Independent of whether their parametrisation is based on
cellular density evolution or on tumour delineation progres-
sion, all of the above macroscopic models focus on the
integration of anatomical medical imaging. Although some
studies have included structural information from Diffusion
Tensor Imaging (DTI) to model the fact that glioma cells
preferentially migrate along white fibres of the brain, no
information on the metabolic and activity status of the cell
densities was included [7], [13].
Some studies have integrated metabolic measures from
medical imaging modalities into a model of tumour growth.
This was done, for example, by linking the biological ag-
gressiveness assessed by a series of MRI with the hypoxic
burden assessed on FMISO-PET [26]; by using PET-MRI data
to constrain a coupled set of partial differential equations to
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describe tumour cell proliferation, angiogenesis, and glucose
consumption [32]; by using hypoxia as a driver of tumour
cell migration described in terms of imaging data (MRI, PET
and SPECT) [4]; or by using Diffusion Weighted MRI and
Dynamic Contrast-Enhancement (DCE)-MRI to parametrise a
logistic model of tumour model and predict the cellular evo-
lution as well as the reaction of tumour to therapy [3].
All of these studies were able to demonstrate the feasibility
of parametrising a model of tumour growth using information
from imaging data. However, due to the lack of subject-specific
data, especially in face of the multi-modality approach, a mix
of parameters from various studies using different types of
cancer needed to be used.
To circumvent the problem of multi-modality and hence
the potential lack of subject-specific data, in this work, we
derived all information needed to drive a model of tumour
growth from a single imaging modality. This modality needs
to be able to provide anatomic information (ideally 3D) whilst
allowing for richer information on microscopic phenomena
to be extracted. Dynamic Contrast-Enhancement (DCE)-MRI,
which additionally to the anatomic MRI information enables
the extraction of physiological parameters related to vessel
permeability, blood flow, and tissue volume fractions was
chosen [27]. It has previously been shown that DCE-MRI
has the potential to predict therapeutic response at the cellular
level [29] and to assess tumour patophysiology by estimation
of tumour cellularity [2], [3].
The contributions of this work are threefold: 1. We design
a subject-specific preclinical tumour growth model that allows
for the inclusion of anatomical information as well as of differ-
ent biological activities (proliferation, hypoxia and necrosis)
extracted from DCE-MRI data; 2. We extend our previous
discrete model [21] used to simulate the 2-D expansion of
the middle slice of the tumour to a 3-D reaction-diffusion
model able to simulate the expansion of tumour volume; 3.
We test our model first on synthetic data to derive the means
to accurately recover model parameters and then on cases of
preclinical breast carcinoma to predict the local cell density for
each cell sub-population (proliferative, hypoxic and necrotic),
as well as the 3-D macroscopic invasion of the tumour in the
host tissue at later time points.
II. METHODS
A. Overview of the Method
Due to its capacity to characterize tumour tissue properties
at the macroscopic and microvascular scales, we use DCE-
MRI time series to build, calibrate and validate our PDE model
and simulate the spatio-temporal evolution of tumours.
The general pipeline is summarized in Fig. 1. Firstly,
local physiological properties of the same tumour at two
consecutive time points T P1 and T P2 are extracted from the
DCE-MRI time series (section II-C) and then converted into
cellularity maps (section II-D). The tumour evolution between
the time points is assumed to follow the PDE model outlined
in section II-B. To make this model tumour-specific, parame-
ters are calibrated by maximizing the similarity between the
transformed cellularity maps of T P1 and the observed cellu-
Input from DCE-MRI at TP1 and TP2
Compute DCE-MRI related
maps (Eq.(12)-Eq.(14))
Compute related cellularity
maps (Eq.(15)-(18))
Use cellularity maps at TP1 to
initialise model (Eq.(7)-Eq.(9))
Use cellularity maps at TP2 to
extract optimal set of parameters
Use optimal parameter set to
simulate tumour growth after TP2
Fig. 1: Overview of a tumour growth model built from DCE-MRI perfusion
imaging data. DCE-MRI related physiological maps are used to compute
proliferating, hypoxic and necrotic cell maps used to initialise the model
expressed as a set of partial-differential equations. This model is solved at
each time step and voxel, to compute the cellularity maps and tumour volume
at a later TP. The true tumour volume at TP2 is used to optimise a set of
parameters, which is in turn used to predict the tumour at a later TP.
larity maps at T P2 using a simulated annealing optimisation
technique (section II-E). The PDE model of section II-B is
finally used to predict the tumour development after T P2
(section II-F) and compared to the tumours observed in the
scans of these time points (section III).
B. Tumour growth model
The tumour growth model presented in this work represents
a multiscale 3-D model consisting of three layers: a macro-
scopic tissue layer to allow for integration of the pre-clinical
imaging data, a cellular layer at which the nutrient is made
available to the tumour cells and a sub-cellular layer in which
metabolic processes depending on the nutrient level can lead
to cell proliferation, hypoxia or necrosis. Changes in the latter
(i.e. mitotic activity, hypoxia and necrosis) result in changes
in the microscopic layer (i.e. local cell number), which in
turn affect the tumour at the macroscopic level (i.e. tumour
expansion and nutrient distribution).
Proliferation has been investigated in various mathematical
models. The most prominent models are given by the logistic
and Gompertz models. Due to its simplicity when compared
to the Gompertz law, the logistic law has been implemented
to our model of tumour growth in the form:
∂c(t)
∂ t
= g(c(t)) , (1)
2
where c(t) is the cell number and g(c(t)) is:
g(c(t)) = p · c(t) ·
(
1− c(t)
Θ
)
, (2)
where Θ the carrying capacity of the voxel obtained by
dividing the voxel volume (here 0.0751mm3) by the volume of
each cell, which is assumed to be a sphere with a diameter of
10µ as given in [3], and p the rate at which cells proliferate.
The solution for this model depicts an S-shape curve. This
means that as time t increases, the cell number c(t) increases
first slowly then more rapidly as the graph approaches a
straight line in the midsection, followed by a slow increase
until finally a saturation state is reached.
As time increases, tumour cells not only proliferate, but
also spatially invade the hosting tissue. To implement spatial
diffusion into pure, temporal proliferating models, Eq. (1)
needs to be extended by the spatial tumour expansion term.
Hence, Eq. (1) for the logistic model becomes a reaction-
diffusion equation as follows:
∂c(x, t)
∂ t
=5· (d(x, t)5 c(x, t))+ p · c(x, t) ·
(
1− c(x, t)
Θ
)
,
(3)
where the carrying capacity of each voxel Θ is introduced
to model the saturation of nutrient.
Because tumour growth is not only the result of unre-
strained proliferation, but also of disorder in cell death and
hypoxia, our model includes the evolution of proliferating,
hypoxic and necrotic cells.
At each time step t, proliferating cells can either divide
following a Gompertz curve, or if their nutrient level is low,
become hypoxic following an exponential decay. In turn,
hypoxic cells can either remain hypoxic or die following an
exponential decay. The maps for the cell division probability
g, the hypoxia transition f and the necrosis transition h are
directly related to the nutrient map η , as follows:
g(η(x, t)) = cg0 exp(−exp(−cg · (η(x, t)− ip)) (4)
f (η(x, t)) = exp(−c f ·η(x, t)) (5)
h(η(x, t)) = exp(−ch ·η(x, t)) . (6)
where cg0 , c f and ch are model parameters. The constant
cg represents the slope of the Gompertz function and is set
to cg = 0.31/mmHg to reach 99% of the asymptote cg0 at
maximal nutrient availability; and ip is the position of the
steepest increase of the nutrient, and therefore the inflection
point of the Gompertz curve. To reduce the number of pa-
rameters, we set ch = 2c f , accounting for the fact that the
transition between hypoxia and necrosis happens at a lower
nutrient level than the one between proliferation and hypoxia,
and assume ip = 15mmHg for all cases.
Expressed as a set of PDEs, the processes described above
can be modelled as follows [22]:
∂ p(x, t)
∂ t
=5· (d(x, t)5 p(x, t))+g(η(x, t)) · p(x, t)
·
(
1− r(x, t)
Θ
)
− f (η(x, t)) · p(x, t) (7)
∂q(x, t)
∂ t
=5· (d(x, t)5q(x, t))+ f (η(x, t)) · p(x, t)
−h(η(x, t)) ·q(x, t) (8)
∂n(x, t)
∂ t
= h(η(x, t)) ·q(x, t) (9)
where p(x, t), q(x, t), n(x, t) and r(x, t) represent the num-
ber of proliferative, quiescent (hypoxic), necrotic and total
cells, with t denoting time and x a spatial coordinate in a
three-dimensional domain. Note that, other than in Eq. (3)
and in most reaction-diffusion models of tumour growth [3],
[7], [11], [13], [15], [24], [26], [28] where the proliferation
rate had a global value, in our work the proliferation rate,
g(n(x, t)), is a function of the nutrient distribution (Eq. 4) and
hence, of time and space1. Once necrotic, cells are removed
from the tumour after a period of 40 hours, modelling the lysis
time [8].
Once necrotic, cells are removed from the tumour after a
period of 40 hours, modelling the lysis time [8].
C. DCE-MRI data to physiological parameters
Dynamic Contrast Enhancement (DCE) MR perfusion
imaging is based on the application of an exogeneous, in-
travascular, non-diffusible contrast agent (CA) and consists
of taking several sequential T1-weighted MR images over a
short period of time upon the injection of a CA. The most
common CA used is the low-molecular-weight gadolinium-
diethylenetriamine pentaacetic acid (Gd-DTPA), which is able
to transverse the vessel walls, thus entering the extracellular-
extravascular space (EES). However, it is unable to cross the
cellular membrane, limiting its volume of distribution (vD) to
the interstitial space. As a result, DCE-MRI signal intensity
changes derive mainly from CA that extravasates to the EES,
which locally enhances the measured signal intensities by
shortening of the longitudinal relaxation time according to its
concentration C(t):
1
T1
=
1
T10
+ r1C(t) (10)
Here, T10 is the relaxation time T1 prior to the injection
of CA, r1 the relaxivity constant specific to CA, and C(t) the
total concentration of CA at time t.
A usual DCE-MRI experiment assumes a tissue sample
with a single inlet through which the arterial plasma flow
F enters the tissue. The measured time curves, the tissue
concentration C(t) and the concentration in the blood plasma
of the feeding artery (the arterial input function, AIF), are
related by convolution with an unknown, tissue-characteristic
impulse response function I(t):
C(t) = I(t)⊗AIF (11)
1The numerical strategy used to solve the system of equations, in particular
Equations (7), (8) and (9), is developed in Appendix-A, which can be found in
the supplementary materials available in the supplementary files/multimedia
tab.
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Several models have been developed to estimate DCE-
MRI related parameters. The first generation dates back to
the works of Tofts and colleagues in the 1990s [27]. Here,
perfusion related parameters (e.g. exchange rates between
individual subspaces) are obtained by fitting a Pharmacokinetic
Tracer Analysis model to C(t). Model-free approaches that
characterize the shape and structure of the signal intensity time
curve S(t) can also be used to quantify tissue perfusion [35].
Further, semi-quantitative parameters (e.g. bolus arrival time,
area under the curve and time to peak) can be computed
directly from the S(t) [20].
For our strategy we are interested in the following physio-
logical quantities from the DCE-MRI time series obtained at
each time point:
• The maximum enhancement peak of the concentration
time curve (mEP),
• the distribution volume (vD) defined as the fraction of
tissue accessible to the CA,
• the blood flow (F),
• the Mean Transit Time (MT T ) which relates vD to the
arterial inlet to the space carrying the plasma flow.
To extract these parameters, we adopt a combination of
the model-free deconvolution method with a semi-quantitative
approach. Note that in this subsection, t indexes the images
of a single DCE-MRI time sequence and not different time
points T Pn, so that it is much smaller here than in sec-
tion II-B.
First, S(t) is converted into CA concentration time curve
C(t) using:
C(t) = 1r1
(
−1
T R ln
{
E(E10−1)+E10[1−cos(FA)]
1+cos(FA)[E(E10−1)−1]
}
− 1T10
)
where E10 = exp(−T R/T10), E = S(t)/S0 and r1 is the longi-
tudinal relaxivity (contrast agent property). T R is the repetition
time (time between two excitation pulses), FA denotes the flip
angle and S0 is the signal at the baseline. It follows that the
C(t) can be extracted from the observed signal enhancement
E, provided that r1, T10 and T R are known. The maximum
enhancement peak of the concentration time curve mEP is
then defined as equal to maxt(C(t)).
Next, the distribution volume vD (the fraction of tissue
accessible to the CA) map for each T P can be computed using
Eq. (12) as given in [23]:
vD =
∫ ∞
0 C(t)dt∫ ∞
0 AIF(t)dt
· (12)
A population based AIF as given in [19], using pre-clinical
values as in [10], was used.
Following Eq. (11), the deconvolution of the measured C(t)
with AIF yields an estimate for the impulse function I(t),
defined as:
I(t) = F ·R(t) · (13)
Here, R(t) represents the residue function, the fraction of
CA remaining in the voxel at a time t after its arrival. For the
deconvolution, a block-circulant singular value decomposition
(oSVD) matrix as described in [31] was used. Applying oSVD
to Eq. (11) and (13), yields the blood flow F as the maximum
of I(t).
The MT T for each voxel can be computed using the
central-volume theorem [34]:
MT T =
vD
F
· (14)
All these parameters quantify the tumour metabolic status,
which is important for the tumour further development.
D. Cellularity maps and related maps
Different maps are needed to initialise, calibrate and verify
our reaction-diffusion model: The number of proliferating cells
(p), the number of hypoxic cells (q), the number of necrotic
cells (n), the total number of tumour cells (r), the nutrient
distribution (η) and the diffusion coefficient of the hypoxic
and proliferative cell densities (d).
Aryal et al. were able to demonstrate that DCE-MRI
derived vD values were significantly, negatively correlated with
tumour cellularity [2]. Building on these findings, to estimate
the total number of tumour cells r at a given voxel location x,
we assume that the higher vD the less space for cells within a
voxel. We also assume that the higher the cellularity, the longer
it will take for the CA to leave the voxel. Hence, a positive
correlation between cellularity and MTT is assumed:
r(x) =
(
MT T (x)
max(MT T (x))
)
· (1− vD(x)) ·Θ · (15)
The number of proliferating cells p is assumed to be
proportional to the peak of maximum enhancement mEP,
based on findings in [9] who were able to demonstrate a
positive correlation between the mitotic index and the peak of
maximum enhancement. It follows that an initial map giving
the number of proliferating cells can be estimated assuming
the following relationship:
p(x) =
mEP(x)
max(mEP(x))
· r(x) . (16)
Cells within a voxel that are not proliferating can either
be in a dormant state (hypoxic) or dead (necrotic). In order
to obtain the number of necrotic cells n, we assume that low
blood flow F , and hence low nutrient availability, results in
high cell death rate calculated as follows:
n(x) =
(
1− F(x)
max(F(x))
)
· (r(x)− p(x)) . (17)
Finally, the number of hypoxic cells q can be estimated as
the difference between the total cell number r(x) and the sum
of p(x) and n(x):
q(x) = r(x)− p(x)−n(x) . (18)
Once the total number of cells in each voxel is known, the
nutrient distribution η(x) is computed using:
η(x) = η0 · [(1−α · r(x))]/[1+(p(x)/γ)] (19)
Here, η0 is assumed to be the level of nutrient of the
host tissue (in the absence of a tumour cell population) which
is equal to the maximum of the nutrient that can be made
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Time point Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 10
c f [1/mmHg] 0.063 0.112 0.072 0.290 0.100 0.1316 0.082
D0[mm2/h] 1.59E-07 2.46E-05 5.5E-05 1.89E-05 5.0E-06 1.82E-05 3.42E-07
TABLE I: Optimized model parameter values used to simulate tumour growth between T P2 and T P5. cg0 was kept fixed at 0.0001 [1/h] for all synthetic and
pre-clinical cases.
available for cells within the tumour. The constants α and γ
are chosen, for simplicity, to be the inverse of the maximum of
the total cell number r and of the proliferative cell number p,
respectively. This is the quasi-steady state solution to
∂η(x)
∂ t = Dη∇η(x)+ k1 ·n0(1−α · (r(x)))− k1 · c− k2 · p(x) ·η(x),
(20)
where γ = k1/k2. This quasi-steady state assumption can be
justified by the disparity in time-scale between the dynamics
of the nutrient field and the movement of the interface (the
diffusion time of oxygen across one cell is on the order of
seconds while cell division occurs on the order of hours). The
first term of the right-hand side can be set to zero, as the
nutrient can be assumed to be consumed locally by cells within
this voxel and not by cells in neighbouring voxels.
We finally assume the isotropic diffusion coefficient d of
both the hypoxic q and proliferative p cell densities to be
related to the total cell number r as follows:
d(x, t) = D0 exp(−r(x, t)/κ) · (21)
κ is chosen to be the maximum of the total cell number, i.e.
1/α , and D0 is a parameter to be optimised to model the fact
that tumours expand at different rates.
E. Estimation of tumour-specific parameters
Parameter maps derived from DCE-MR images at T P1 are
used to initialise the model. In order to predict the tumour
evolution after T P2 using the model of section II-B, the
parameters cg0 , c f and D0 have to be estimated.
Our estimation problem can be defined as:
min
cg0 ,c f ,D0
vole(cg0 ,c f ,D0)
s.t. 0.0001≤ cg0 ≤ 0.01 1/h
0.05≤ c f ≤ 0.3 mmHg/h
1x10−7 ≤ D0 ≤ 0.01 mm2/h
(22)
where vole = |(vols − volt)/volt | is the relative volume
estimation error between the volume observed at the true
scans in T P2 which have been manually delineated by a
radiologist (volt ), and the simulated volume, vols, obtained
by producing an apparent boundary on the simulated tumour
based on r(x,T P2). The cellularity maps are simulated solving
the set of PDEs (Eq. 7-Eq. 9). Their initial states are computed
at T P1 using the methods described in II-C and II-D. Due to
the diffusion term, all voxels of r(x,T P2) might contain some
tumour cells even if they would not be visible on a scan. In
order to delineate the simulated tumour, we assume a voxel x
to be outside the tumour if less than 1% of its carrying capacity
is made out of tumour cells, i.e. if r(x,T P2) < 0.01Θ. Note
that this PDE-constrained optimisation problem is nonconvex
and computing vole gradients would be costly. We then use a
global optimisation strategy, the built-in simulated annealing
MATLAB function [14], to optimise Eq. 22 and hence estimate
cg0 , c f and D0.
F. Predicting the tumour spatio-temporal growth
Once the parameters cg, c f and D0 are estimated be-
tween time points T P1 and T P2, the obtained values after
optimisation (see Tab. I) are used as input for the tumour
growth simulation between T P1 and T P5. After simulation,
the output, represented by the simulated cellularity maps and
the simulated tumour volume, was compared to the maps
acquired at the respective time points.
We also compare the simulated tumour volumes with the
true volumes observed in the actual scans in terms of the Dice
similarity coefficient DSC. This statistical validation metric,
normally used to evaluate the performance of segmentation
tools in terms of spatial overlap accuracy, can be calculated
using DSC = 2A∩BA+B , where A is the simulated tumour image
and B the true tumour image at a given T P.
The calibration process takes on average 14.84±4.79 hours
and around 1500 iterations over the 3D growth simulation
between T P1 and T P2 until convergence is achieved. For the
prediction post T P2, each run takes up to 3 minutes depending
on the size of the tumour being modelled. All codes were
written in Matlab (Mathworks, Natick, MA) and all simula-
tions performed on a 3.4 GHz Intel Xeon machine with 32GB
of RAM, providing scope for reducing the optimisation time
using more efficient implementations or parallelization.
G. Experiments
1) Sensitivity analysis: To explore whether all of our
parameters influence our model outcome, we performed a sen-
sitivity analysis using the eFAST method as described in [16].
The reference outputs were r(x) and vols. To determine the
significance of the eFAST first-order indexes we followed the
procedure described in [16] and included a dummy parameter
into the analysis. Parameters with a sensitivity index with less
than that of the dummy parameter should be considered not
significantly different from zero.
2) Synthetic data: In order to evaluate our parameter esti-
mation method, we performed tests with 15 different synthetic
tumours generated using 15 different parameter sets within the
ranges given in Eq. 22. For each tumour the model is initialised
using maps for T P1 from one of the available pre-clinical
DCE-MRI extracted following section II-D and simulations
were performed for four days, i.e. up to T P5. We note that no
noise has been added to the simulation since the relationship
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between MR signal noise and the noise seen in our input
(cellularity maps) is not known and its analysis would exceed
the scope of the current study.
3) Pre-clinical data: Ten mice, in which CaNT (breast
carcinoma) tumour cells were injected, were imaged at five
consecutive days over the tumour growth cycle (starting 10
days after injection). We denote T Pn the time point of the nth
acquisition. DCE-MRI was performed at 4.7 T (Varian VN-
MRS) with 60 repeats (DCE frame rate of 10-15 seconds) of
a cardio-respiratory (CR-) gated RF and gradient spoiled 3-D
gradient echo scan (TR1.4 ms, TE=0.64 ms, FOV=54×27×27
mm3, matrix=128×64×64, hard pulse=16 µs and FA=5◦).
Anaesthesia was maintained with 1-3% isoflurane in a 1:5
O2:air mixture. Respiration was monitored using a pressure
balloon. ECG needles were placed subcutaneously in the chest.
Motion artefact was minimised with automatic and immediate
reacquisition of data corrupted by respiration motion. Gd3+
was automatically infused into the lateral tail vein triggered at
the start of scan 11/60. Sporadically, the Gadolinium injection
failed, which hindered the acquisition of the DCE-MRI for
T P1 for Case 3, T P2 for Cases 8 and 9, T P3 for Case
1, T P4 for Case 9 and T P5 for Cases 3 and 4. T10 was
determined prior to DCE-MRI from a variable flip angle (VFA)
scan [6] with the same CR-gated 3-D gradient echo scan and
16 nominal FAs ranging from 1◦to 7◦in steps of 0.4◦. 3-D
B1 maps to quantify FA prescription were acquired with a
respiration gated actual flip angle imaging (AFI) scan [33] and
TR1=10 ms, TR2=100 ms, TE=0.42 ms and nominal FA=64◦.
Due to missing information for T P2 Cases 8 and 9 were
excluded from the analysis. Likewise, we needed to exclude
Case 7 because the tumour did not grow but shrank between
T P1 and T P2. Therefore, excluding these three cases, our used
sample will be referred to as seven cases.
III. RESULTS
A. Synthetic data
Similar to findings in [15], [24], we observed that different
combinations of cg0 and D0 yield same results. The sensitivity
analysis, a total of 1285 model evaluations, yielded first-order
sensitivity indexes of 0.8571, 0.2761 and 0.0048 for D0, c f
and cg0 , respectively. Applying the dummy parameter eFAST
method to our model, we found c f and D0 to be significantly
different from zero. These results imply that our model is
mostly influenced by the diffusive character of tumour growth
and thus we fix parameter cg0 for further analyses.
Using T P1 and T P2 for calibration yielded mean rela-
tive errors between true and estimated values of 0.71 and
0.23 for c f and D0, respectively. Using the recovered pa-
rameters as input for simulations between T P3 and T P5
resulted in 4.78±8.26%, 3.55±4.95% and 3.81±6.05% vol-
ume error, respectively. The DICE-overlap between true
and estimated volumes were 97.78±3.6%, 98.30±2.29% and
98.20±2.74%.
B. Pre-clinical data
1) Cellular evolution simulations: The initial total cell
number for each sub-population and total cell number are
computed as the sum of the cells over the voxels within the
tumour boundaries at T P1. Using the optimised parameters
given in Tab. I, for each time step, the total cell number
for each sub-population is computed and used as input for
the consecutive time step. The evolution of the proliferating
(blue), hypoxic (green) and necrotic (yellow) for all Cases and
time points (T P2−5) are shown in Fig. 2-a. The red crosses
represent the true total cell numbers computed as a sum over
the voxels within the true masks used for validation. Missing
columns are due to missing data for some cases.
Figure 2-b shows the mean absolute cell error for pro-
liferating (blue), hypoxic (green) and necrotic (yellow) for
all cases. The error increased with time, so that predictions
for later time points (T P5) had higher errors than for earlier
time points (T P3). Additionally, the higher errors were linked
to an overestimation in the number of necrotic and hypoxic
cells. Relative errors for total number of cells were 0.76±0.67,
1.04±0.94, 1.65±1.73 and 2.69±2.41 for T P2, T P3, T P4 and
T P5, respectively (see Fig. 2-c).
2) 3-D growth simulations: On average for all seven cases
using the model resulted in a DSC 60.25±10.60, 53.18±16.29
and 50.72±17.43, for T P3, T P4 and T P5, respectively. At
later time points the relative volume estimation error increased
from 0.45±0.40 at T P3 to 1.23±1.08 at T P5.
Figure 3 compares the true and estimated cell distributions
for a middle slice of the tumour volume evolution for Case
10. From left to right we show true, estimated and residual
cell maps for T P2, T P3, T P4 and T P5, respectively. For the
true and estimated maps, the colour bar represents the number
of cells relative to the voxel cell capacity and hence, ranges
from 0 to 1. For the residual maps, computed by subtracting
the true from the estimated maps, the colour bar ranges
from -1 to 1. Hence, negative and positive values represent
a local underestimation and overestimation in the estimated
cell number, respectively. The black and red outlines within
the difference maps represent the true and estimated tumour
margin, respectively. The simulated sizes and directions of
tumour growth are similar to the ones seen in the true
images, especially for early time points. For T P5 areas of
overestimation can be generally observed at the periphery
of the tumour. For T P3 and T P5, the true images depict
parts of the tumour for which no cellularity quantities could
be extracted, presumingly where no signal enhancement was
achieved due to the presence of necrosis. In the simulated maps
those areas depict a smaller cell number but are not completely
empty of cells.
IV. DISCUSSION AND CONCLUSIONS
We have presented a reaction-diffusion model of avascular
tumour growth constrained by quantitative DCE-MRI data to
predict tumour spatio-temporal growth. We first used synthetic
data to evaluate our model and its predictive power. Encour-
aged by our results on synthetic data, we applied our model
to data obtained from DCE-MR images for seven preclinical
cases of breast carcinoma. Our results demonstrated the fea-
sibility of using maps of cellularity obtained from DCE-MRI
analysis to feed and calibrate a model of tumour growth to
obtain subject-specific predictions of tumour evolution.
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Fig. 2: Simulated tumour cell evolution proliferating (blue), hypoxic (green) and necrotic (yellow) for all cases and time points (T P2−5) are illustrated as a
block-diagram (a). The red crosses represent the true estimated cell number at T P2, T P3, T P4 and T P5. Panel (b) and (c) show the mean absolute cell error
for proliferating (blue), hypoxic (green) and necrotic (yellow) and the relative error for the total cell number for all cases, respectively.
The results on our synthetic experiments demonstrate that
fixing cg0 allowed us to accurately predict future tumour
growth, manifested in small volume errors and large Dice
values, as compared to other studies in the field. For instance,
in [12] Diffusion Weighted-MR images were used to constrain
a reaction-diffusion model of glioma growth. The in silico
results showed a percent error in tumour volume ranging
between 3.1% and 36.4% and 0.8% and 8.8% when using two
and three time points for calibration, respectively. Similarly,
in [15] the authors assessed their estimation results based on
delineation variability values found their results to be less than
a variability value of 0.2mm2, which for their tumour translates
in a volume error estimation of less than 10%.
The higher cellular prediction and relative volume errors
observed at later time points may be due to four reasons.
Firstly, the period between the images used for calibration
was one day (T P1 until T P2), so that using the optimised
parameters for simulation from T P2 onwards might only allow
us to predict the volume of the tumour for the same period,
i.e. up until T P3 (day 3). Secondly, for later time points
we expect the tumour to have undergone angiogenesis. Our
model, however, does not include angiogenesis, and as such
only simulates avascular tumour growth. Thirdly, the largest
discrepancy observed in Fig. 2 is linked to the necrotic cell
estimation which can be linked to the fact that apoptosis (cell
natural death) was not included in our model. To minimise
the relative volume error at later time points, we need to
investigate whether using T P1 and T P3 or, as suggested by
[12], using three time points to calibrate the model would
result in better estimations for T P4 and T P5. Finally, the
fact that no noise has been added to the synthetic data during
analysis can also be a potential source of error when dealing
with real data and will be explored in a future study.
Our results in Fig. 2 demonstrate that our model per-
forms better for some cases (e.g. Cases 1 and 10) than
others (Case 5 and 6), showing that even within a controlled
experiment, using the same sort of subjects and cell lines,
tumour progression can vary hugely due to subject-specific
microenvironmental aspects. This serves as a motivation to
further personalise our model by including information from
the surrounding of the tumour which could give additional
information to drive tumour expansion. For instance, one could
use MRI-Elastography to generate a stiffness map, which
could serve as a measure of tissue resistance. Here, the tumour
growth would proceed along the lines of the least physical
resistance [30].
Figure 2 demonstrates that using cellularity maps from two
early time points of tumour development we were able to
predict within a reasonable error margin the overall number of
cells at later time points. Accounting for each sub-population
evolution in addition to the overall volume growth is a strength
of the current model compared to other works where all
cells within the tumour or a given voxel are assumed to be
active and divide at the same proliferation rate [7], [12], [25].
Our model has the potential to evaluate how each cell group
contributes to tumour evolution. For instance, in our results,
the biggest increase can be seen in the number of necrotic
cells suggesting that most of our tumour growth is due to the
emergence and growth of necrotic rather than to proliferative
areas. In addition, the hypoxic cell numbers could be used
to aid treatment planning, as hypoxia is known to play an
important role in treatment outcome. However, our results
demonstrate that even if the model can predict the total cell
evolution within a small range of errors (see Case 10 e.g), it
is not able to distribute the cells into the three sub-categories
correctly, represented especially by an overestimation in the
number of hypoxic and necrotic cells and an underestimation
in the number of proliferating cells.
To the best of our knowledge, this is the first attempt to
quantify the number of proliferative, hypoxic and necrotic cells
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Fig. 3: True and estimated cell distributions for Case 10. The true (left column) and the estimated (middle column) relative cell distributions for an example
pre-clinical case are shown for T P2, T P3, T P4 and T P5. In the right column, for a central slice of the tumour volume, we show the residual maps obtained by
subtracting the true maps from the estimated maps. The black and red outlines displayed within the residual images represent the true and estimated tumour
delineation, respectively.
using only DCE-MRI maps. Therefore, in the future a compar-
ison of the parameter maps to histo-pathological data should be
included in order to validate these maps. Alternatively, because
oxygen is the leading nutrient in our model, further tuning of
this parameter, e.g. using FMISO-PET scans, could lead to an
improvement of the estimation of each cell subpopulation and
of the 3D- growth prediction. However, even prior to histo-
pathological validation, the comparison between simulated
results and the preclinical data shows that the macroscopic
growth behaviour of the tumour could be well reproduced. The
volume errors could be further reduced by choosing a different
diffusion law, which could for instance follow an interstitial
pressure gradient instead of the cell gradient implemented
herein. Such an interstitial pressure map could be computed
using DCE-MRI as proposed by [1].
Even when lysis time is considered, the model fails at
predicting some necrotic areas (such as the ones seen in the
true maps shown in Fig. 3). This might be linked to our
assumption that the tumour centre of mass remains constant
over its evolution, so that voxels in the centre of the tumour
are assumed to correspond over time. When this is not the
case, voxels which were necrotic (and hence empty) at T P1
but populated in T P2 might not be the corresponding voxels.
As a result, in the simulated cell maps for T P2 the voxels will
be populated and their cells will continue to proliferate, turn
hypoxic or die depending on their nutrient level.
To simplify our model, the simulations were limited to
a constant evolution of the nutrient field. For more realistic
results, in the future, the nutrient field will evolve following a
PDE of the type Eq. 20 and added to the PDE system. This
will enable the inclusion of angiogenesis, ultimately allowing
for cells in different parts of the tumour to proliferate, turn
hypoxic or die independently of their location in the tumour,
as nutrient would be provided by small local vessels.
While our model had been built on preclinical data with
as many as five time points for imaging tumour growth - a
scenario not commonly available in a clinical setting -, our
methodology uses only two time points for calibration and
one data point for verification, which opens the opportunity
to investigate clinical data where therapy is being delivered,
using one time point prior to, one during and one post-therapy.
To account for therapy, the model needs to be extended
accordingly. Such an update could e.g. include the effect of
hypoxia on the outcome of therapy. For this, having included
hypoxia and nutrient maps in our current model already is
a step towards allowing for different therapy outcomes in
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different positions and cell groups within the tumour to be
modelled. Such an approach could be supported by preclinical
data to calibrate and verify the tumour therapy response model
prior to clinical application.
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